Encyclopedia entry
Ipamorelin
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-20
Ipamorelin is a synthetic pentapeptide and selective growth-hormone secretagogue (a peptide that triggers the pituitary to release endogenous growth hormone), originally developed by Novo Nordisk in the late 1990s. Unusually for a research peptide, ipamorelin reached phase II human clinical trials, in postoperative ileus, before development was discontinued for failing to meet endpoints. It holds no marketing authorisation in any country. In the UK it is sold by research-peptide retailers under "research use only, not for human or animal consumption". PeptideClear publishes encyclopedia commentary only and does not endorse human use.
Pharmaceutical development history
- · Discovered and developed by Novo Nordisk, late 1990s.
- · Phase II human trials in postoperative ileus (Helsinn licensee, 2000s).
- · Endpoints not met. Programme discontinued.
- · No further pharmaceutical development since.
- · Available now only via research-peptide retailers under "research use only" framing.
Why this entry exists
Ipamorelin is unusual because it has phase II human safety data, unlike most research peptides. That does not make it a medicine. It was tested for a specific indication (postoperative ileus) and failed. Any present-day human use is off-label and unsupervised. We do not publish dosing or protocols. The encyclopedia entry exists to give readers access to the regulatory and pharmaceutical history they will not find on retailer pages.
Where to buy Ipamorelin in the UK
Side-by-side price comparison across UK research peptide retailers. Trust Index ranking. Research use only.
Compare UK retailersPopular on PeptideClear
Ready to buy
Buy IPAMORELIN in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.